Literature DB >> 11591432

Reliability and validity of the Panic Disorder Severity Scale: replication and extension.

M K Shear1, P Rucci, J Williams, E Frank, V Grochocinski, J Vander Bilt, P Houck, T Wang.   

Abstract

UNLABELLED: The Panic Disorder Severity Scale (PDSS) is a recently developed seven-item instrument to rate overall severity of Panic Disorder. The scale has previously shown good psychometric properties in a sample of Panic Disorder patients with no more than mild agoraphobia. The purpose of this paper is to confirm reliability and validity, to provide an estimate of a cut-score discriminating the presence or absence of current DSM-IV Panic Disorder, and to determine the factor structure of the instrument. PROCEDURES: 104 psychiatric outpatients, including 54 with current Panic Disorder, underwent structured diagnostic assessment and the PDSS interview. The PDSS was repeated within 3-17 days.
RESULTS: we confirmed reliability and validity of the instrument and found a one-factor solution fit the data. A cut-off score of eight identifies patients with current panic with a sensitivity of 83.3%, and a specificity of 64%.
CONCLUSION: the PDSS is a simple, reliable instrument for use in Panic Disorder studies. A cut-score of eight may be useful as a tool to screen patients in settings such as primary care, for diagnosis-level symptoms.

Entities:  

Mesh:

Year:  2001        PMID: 11591432     DOI: 10.1016/s0022-3956(01)00028-0

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  85 in total

1.  The Development of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders: A Case Study.

Authors:  Christina L Boisseau; Todd J Farchione; Christopher P Fairholme; Kristen K Ellard; David H Barlow
Journal:  Cogn Behav Pract       Date:  2010-02

2.  Health care use and quality of life among patients with asthma and panic disorder.

Authors:  Jonathan M Feldman; Paul M Lehrer; Soo Borson; Teal S Hallstrand; Mahmood I Siddique
Journal:  J Asthma       Date:  2005-04       Impact factor: 2.515

3.  Respiratory and cognitive mediators of treatment change in panic disorder: evidence for intervention specificity.

Authors:  Alicia E Meuret; David Rosenfield; Anke Seidel; Lavanya Bhaskara; Stefan G Hofmann
Journal:  J Consult Clin Psychol       Date:  2010-10

4.  Rest-activity rhythm profiles associated with manic-hypomanic and depressive symptoms.

Authors:  Stephen F Smagula; Robert T Krafty; Julian F Thayer; Daniel J Buysse; Martica H Hall
Journal:  J Psychiatr Res       Date:  2018-04-21       Impact factor: 4.791

5.  Acid-sensing T cell death associated gene-8 receptor expression in panic disorder.

Authors:  Jeffrey R Strawn; Lauren L Vollmer; Katherine M J McMurray; Jeffrey A Mills; Sarah A Mossman; Sara T Varney; Heidi K Schroeder; Renu Sah
Journal:  Brain Behav Immun       Date:  2017-07-20       Impact factor: 7.217

6.  The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Robert Jin; Ayelet Meron Ruscio; Katherine Shear; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2006-04

7.  N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.

Authors:  Ovsanna Leyfer; Aubrey Carpenter; Donna Pincus
Journal:  Child Psychiatry Hum Dev       Date:  2019-04

8.  Psychological treatment of comorbid asthma and panic disorder in Latino adults: Results from a randomized controlled trial.

Authors:  Jonathan M Feldman; Lynne Matte; Alejandro Interian; Paul M Lehrer; Shou-En Lu; Bari Scheckner; Dara M Steinberg; Tanya Oken; Anu Kotay; Sumita Sinha; Chang Shim
Journal:  Behav Res Ther       Date:  2016-09-17

9.  The role of panic-fear in comorbid asthma and panic disorder.

Authors:  Jonathan M Feldman; Mahmood I Siddique; Nigel S Thompson; Paul M Lehrer
Journal:  J Anxiety Disord       Date:  2008-07-01

10.  Early intervention in panic: randomized controlled trial and cost-effectiveness analysis.

Authors:  Peter Meulenbeek; Godelief Willemse; Filip Smit; Anton van Balkom; Philip Spinhoven; Pim Cuijpers
Journal:  Trials       Date:  2008-11-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.